ClinicalTrials.gov
public full text
Public Domain
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein#1279419
- Immune System Related Kidney Disease#253137
- Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis#1128206
- Rituximab to Prevent Recurrence of Proteinuria#1440236
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects#1184995
Record · ID 1498033
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive